476060 — Onconic Therapeutics Income Statement
0.000.00%
Last trade - 00:00- KR₩230bn
- KR₩187bn
- KR₩15bn
Annual income statement for Onconic Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 60 | 95 | 21,056 | 14,838 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 8,402 | 14,933 | 18,825 | 19,636 |
| Operating Profit | -8,342 | -14,838 | 2,231 | -4,798 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -15,149 | -14,432 | 662 | -9,942 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -15,149 | -14,432 | 1,682 | -8,093 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -15,149 | -14,432 | 1,682 | -8,093 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -15,149 | -14,432 | 1,682 | -8,093 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -1,402 | -1,336 | 156 | -749 |
| Dividends per Share |